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were driven by the lower costs of oral administration relative to subcutaneous injection 
and a lower rate of long-term complications. A number of one-way sensitivity analyses 
showed that the model was robust. CONCLUSIONS: Rivaroxaban dominates enoxa-
parin as prophylaxis against VTE following THR and TKR in Korea, reducing overall
costs and improving health outcomes.
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OBJECTIVES: To evaluate the cost-effectiveness of dabigatran etexilate (DGB) com-
pared to enoxaparin in the prevention of venous thromboembolism (VTE) following 
total hip replacement (THR) or total knee replacement (TKR) from the perspective of 
the Portuguese NHS. METHODS: DBG (220 mg once daily) was compared to enoxa-
parin (40 mg once daily) in patients undergoing THR (prophylaxis 28–35 days) and
TKR (6–10 days). A decision tree was used to model the ten week post-surgery acute
phase. A Markov process modeled long-term events such as recurrent VTE, post-
thrombotic syndrome and intracranial hemorrhage for patient’s remaining lifetimes. 
Relative risks for VTE and bleed events were derived from the DBG phase III trials, 
RE-NOVATE and RE-MODEL which compared DBG with enoxaparin 40 mg once
daily. Published longitudinal studies were used to estimate the probabilities of long-
term events. Resource use associated with administration of the prophylaxis and the 
management of clinical events was obtained from a national multi-centre prospective 
study involving 50 patients. Unit costs were taken from national sources. Utility
weights were taken from published international literature. RESULTS: VTE and bleed-
ing rates were similar for DBG and enoxaparin. DBG was marginally more expensive 
than enoxaparin in TKR but less costly in THR, since no nursing time for administra-
tion of treatment is required in hospital or following discharge. The probabilistic 
analysis estimated that DBG cost an additional €11 per patient in TKR (ICER €2,848 
/QALY) and saved €255 per patient in THR. The probability of DBG being cost-
effective was 79% in TKR and 99% in THR at a willingness to pay threshold of 
€20,000 per QALY. Results proved to be robust across a wide range of sensitivity 
analyses. CONCLUSIONS: DBG is cost-saving in THR compared to enoxaparin and 
non-inferior in terms of efﬁ cacy or safety. Thus, DBG is cost-effective for the preven-
tion of VTE in patients undergoing THR.
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OBJECTIVES: Atrial Fibrillaion (AF) is a major cause factor for stroke with signiﬁ cant 
burden on Health care system and individuals and “silent” (asymptomatic) AF
episodes are challenging to diagnose. Current diagnostic procedures (Holter-
Monitoring, ECG) alongside clinical evaluation under-detect AF in post-radiofre-
quency catheter ablation (RCA) patients because of the relatively short monitoring
period. The Insertable Cardiac Monitor (ICM) is a programmable monitoring system
that continuously monitors the patient and detects and store arrhythmia events and 
related diagnostic information. The major beneﬁ t to patients is the potential to dis-
continue oral anti-coagulations (OAC) if AF can be convincingly shown to have been
cured. This study assesses the cost-effectiveness of ICM in post RCA patients in the 
Canadian health care context. METHODS: A Markov model was developed to assess
the cost-effectiveness of standard medical care compared to ICM use from a Canadian
provider perspective. The time horizon was three years (four Markov Cycles). The 
main outcome was detecting asymptomatic episodes of AF, which was derived from 
published literature. The frequency of resources used (i.e., risk of stroke and utility 
scores) and associated costs were derived from literature and the Ontario Health
Insurance Policy. RESULTS: The incremental cost-effectiveness ratio (ICER) within 
four Markov cycles was $19,660/QALY which was well below the $50,000 accept-
ability threshold indicating that ICM is cost-effective in post RCA patients. Probabi-
listic sensitivity analysis showed model sensitivity to the QoL gain. However, at 95%
CI the model was still within the acceptability range (0.162–0.24) $19,660$52,730/
QALY. CONCLUSIONS: ICM is a safe, accurate and useful device for detecting 
asymptomatic AF in post-ablation patients. The cost of ICM is partially offset by 
savings in hospital setting due to potential savings from discontinuation of OACs and
costly adverse events. A societal perspective will reduce the ICER in favour of ICM 
by an increase in patients HRQoL.
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OBJECTIVES: Cost-effectiveness analyses of new treatments for cardiovascular 
disease frequently require input parameters whose values are known with uncertainty 
due to limited data. The objective of this paper is to determine the extent to which
published sensitivity analyses adhere to Health Technology Assessment (HTA) guide-
lines. METHODS: We performed a systematic review of published cost-effectiveness 
analyses for an example drug treatment scenario, dual oral antiplatelet therapy com-
pared with aspirin alone following acute coronary syndromes (ACS) and/or percutane-
ous coronary intervention (PCI). We searched for articles published in English from 
1997 to mid-2008 in PubMed, Cochrane Collaboration, EMBASE, and Health Eco-
nomic Evaluation Database (HEED). A total of 216 articles were identiﬁ ed: PubMed,
40; Cochrane, 27; EMBASE, 114; HEED, 35. Of these, 106 articles were unique, and 
16 were included in this review; all selected articles compared clopidogrel plus aspirin 
versus aspirin alone for patients with ACS and planned PCI. We created evidence 
tables to show the sensitivity of the cost-effectiveness estimates to changes in the input 
parameter values, as well as the data sources used for the reference-case and alternative 
estimates for different input parameter values. We also examined the extent to which 
the sensitivity analyses adhered to HTA guidelines. RESULTS: Cost-effectiveness ratios 
were most sensitive to changes in the efﬁ cacy of dual antiplatelet therapy and refer-
ence-case model assumptions about costs beyond the trial period. Although the alter-
native values tested in the sensitivity analysis for some input parameters were based 
on observed ranges or distributions, the alternative values tested for many other input 
parameters were assumed without justiﬁ cation. CONCLUSIONS: The sensitivity 
analyses of the cost-effectiveness studies of dual oral antiplatelet therapy were not 
fully adherent with HTA guidelines. In particular, long-term costs and beneﬁ ts were 
not always included in the reference case and justiﬁ cation of the alternative parameter 
values was not always provided.
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OBJECTIVES: To evaluate the incremental cost-effectiveness of four angiotensin 
receptor blockers in hypertension, in a large US managed care setting. METHODS:
A decision analytical model was developed to estimate costs to reach JNC-7 blood
pressure (BP) goal for four ARBs: olmesartan (OLM), valsartan (VAL), irbesartan
(IRB), and losartan (LOS). The study period was 5/1/01 to 12/31/06. Patients were 
q18 years, have q2 claims for the Index ARB, a medical claim for HTN (ICD-9 codes
401.xx-404.xx), and minimum 6 months pre- and 9 months post-index eligibility. 
Outcomes were all-cause and HTN-attributable actual plan costs to achieve JNC 7 
goal (140/90, 130/80 with diabetes mellitus, DM). Costs were calculated for over 
120,000 eligible patients receiving ARBs in the plan. BP goal attainment was deter-
mined from 1293 medical charts and linked to costs in the claims database. Model 
robustness was tested using Monte Carlo simulation and probabilistic sensitivity 
analysis (PSA). RESULTS: 121,472 patients met inclusion criteria. Mean age was 55.2 
years, 22 % had DM. ARB cohorts were (n) OLM (19,525); VAL (59,176); IRB 
(17,226) and LOS (25,546). OLM was found more effective in achieving JNC 7 goal, 
and to incur lower all-cause and HTN-attributable costs, dominating other options. 
The CE ratios per percent of patients to reach HTN goal for OLM were $8,964 (all-
cause costs) and $2,704 (HTN-attributable costs), compared to the ratios for LOS 
($10,848 and $3,291), VAL ($10,557 and $3,577) and IRB ($13,397 and $4325). (All
costs adjusted to 2006 CPI). Monte Carlo and PSA results were consistent with the
baseline analysis. CONCLUSIONS: Compared to VAL, IRB and LOS, OLM was
found to be the most cost-effective of the four ARBs for the treatment of hypertension 
in a large US managed care population.
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OBJECTIVES: To estimate cost-effectiveness of either the public health strategy of 
increasing tobacco taxes or implementing smoking bans in public venues as a strategy 
for anti-tobacco use. METHODS: Quit and mortality rates for smokers and nonsmok-
ers were obtained from extant published literature and incorporated into a Markov 
Chain Monte Carlo model. The model included the public policies of taxes or bans 
accounting for the incidence of acute myocardial infarction (AMI) and related mortal-
ity. The model incorporated the value of statistical life, and medical costs associated 
with AMI. RESULTS: The expected life years under conditions of taxes, bans, or
neither (base case) were similar at 60.23, 60.25, and 60.37 per smoker respectively. 
Implementation of bans resulted in net societal losses of $1476 and taxes $984 per 
smoker over the “no policy” condition. Costs were lowest under the strategy of 
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increasing per pack taxes by at least 10%, but smokers’ lives were slightly extended 
by the ban condition. Incremental cost effectiveness ratios for taxes and bans, relative 
to no intervention were: $29,827 and $29,814 per life year gained, respectively.
CONCLUSIONS: Both public policy strategies of taxes and bans have a minimal 
impact on life years gained over the lifetimes of smokers. Taxes showed an advantage 
in lower hospitalization and value of lives saved. In addition, taxes are revenue enhanc-
ing, while bans require additional enforcement resources. Using tobacco taxes to 
reduce tobacco consumption and subsequent tobacco-related disease is superior to
smoking bans, though the combination of the two policies may be mutually reinforcing
for behavioral change and additive in effect.
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OBJECTIVES: Clopidogrel is a frequently used drug to prevent subsequent
atherothrombotic events in patients with stroke, myocardial infarction, or peripheral
arterial diseases. Doctors should subjectively determine whether the price of clopido-
grel is justiﬁ ed by its improved therapeutic effect compared to that of aspirin, consider-
ing country-wise economic situation. This study analyzed the cost-effectiveness
of clopidogrel for atherothrombosis treatment in South Korea. METHODS: Cost-
effectiveness was analyzed using the Cambridge model; a Markov model developed
using data from the Clopidogrel versus Aspirin in Patients at Risk of Ischemic 
Events (CAPRIE) study, as per Korean situation. The effect was estimated using
data from the Framingham and Saskatchewan databases to calculate the expected
survival (in years) for various health states. Direct medical costs from the social 
perspective, direct non-medical costs, and indirect medical costs were analyzed;
applying 5% discount rate to both cost and effect. RESULTS: The 2-year follow-up 
results showed that the number of cardiovascular (CV) events and CV deaths per
1000 patients was decreased by 13.19 and 2.21, respectively, in the clopidogrel
group as compared to the aspirin group. As clopidogrel treatment decreased the inci-
dence of CV deaths; the number of life-years gained per 1000 patients was 65.65
(Framingham) and 48.20 (Saskatchewan). The incremental cost-effectiveness ratio 
determined using incremental costs per life-year gained was US$ 19,017 (Framingham) 
and US$ 25,904 (Saskatchewan). CONCLUSIONS: Our results showed that clopido-
grel was cost-effective treatment of atherothrombosis in South Korea, and evaluated 
a basis for the economic feasibility of clopidogrel administration for atherothrombosis 
treatment.
PCV45
ECONOMIC ANALYSIS OF THE INSERTABLE CARDIAC MONITOR IN
DIAGNOSIS OF SYNCOPE COMPARED TO CONVENTIONAL 
DIAGNOSTICS: A CANADIAN PERSPECTIVE
Sadri H1, Tsintzos S2, Winsor P3, Yee R4
1Medtronic of Canada Ltd, Toronto, ON, Canada, 2Medtronic International Trading Sarl, 
Tolochenaz, Vaud, Switzerland, 3Medtronic of Canada, Mississauga, ON, Canada, 4London
Health Sciences Centre, London, ON, Canada
OBJECTIVES: Syncope is a signiﬁ cant burden on the health care system and individu-
als. Screening manoeuvres including medical examination, ambulatory external moni-
toring, imaging and clinical diagnostic tests provide a presumptive diagnosis in a 
limited number of patients since syncope recurrence is unpredictable. Establishing or 
ruling out a cardiac arrhythmia as the cause is challenging, time consuming and relies 
on recording the cardiac rhythm at the time of spontaneous recurrences. The Insertable
Cardiac Monitor(ICM) is a new, efﬁ cient and accurate technique for long-term
monitoring and recording the “events” in a patient. This study assesses the cost-
effectiveness of adding the ICM to the standard diagnostic protocol in Canadian
health care system. METHODS: A decision analytic model was developed assessing 
the cost-effectiveness of the standard diagnosis approach compared to ICM from 
a Canadian provider perspective. The main clinical outcome used in the model
was “yield” deﬁ ned as the rate of correct diagnoses derived from published literature.
The frequency of resources used and associated costs were derived from literature
and the Ontario Health Insurance Policy. RESULTS: The diagnosis yield for ICM
and standard approach was 33.7% and 4.1% respectively. The model assessed
the cost per diagnosis in the two arms. The incremental cost per diagnosis was $6237 
in favour of ICM. Sensitivity analysis showed that in the lower conﬁ dence interval 
(CI) the ICM is the “dominant” option and in upper CI limits the ICER was $35,358
and below the $50,000 acceptability threshold. CONCLUSIONS: ICM is a safe,
accurate and effective device for diagnosis of syncope and should be considered as
an alternative in diagnosis of syncope. The cost of ICM is partially offset by savings 
in hospitalization. A societal perspective will reduce the ICER in favour of ICM by 
preventing complications of syncope (i.e., falls, fractures, mortality) and increase
patient HRQoL.
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OBJECTIVES: To determine the cost-effectiveness, from the Brazilian Ministry of 
Health perspective, of Fluvastatin IR 20 mg, Fluvastatin IR 40 mg, Fluvastatin IR
80 mg and Fluvastatin XL 80. Also we calculated the budget impact of introducing
Fluvastatin XL 80 mg into the current Brazilian national drug formulary. METHODS:
The cost effectiveness was determined using clinical data from published systematic
review and cost the costs were valued using government prices. The costs was in Brazil-
ian reais (BRL) and the price year was 2008 (1$US  1.63 BRL). The beneﬁ t measure
used in this economic evaluation was LDL- reduction. Using the Healtchare System
database’ data we described the evolution of consumption of statins in Brazilian
Health System. Univariate sensitivity analysis tested model robustness. We calculated 
the budget impact analysis for three years. RESULTS: The Fluvastatin XL 80 mg is
the statin more cost-effective and permits the cost reduction in BRL $26,10 per patient.
The sensitivity analysis of budget impact show that introduction Fluvastatin into for-
mulary could generate average savings of 18% of the Fluvastatin’s total budget or 
BRL 56,500 ($US 34,600). CONCLUSIONS: The inclusion of Fluvastatin XL 80 mg 
is aligned with the health authority strategy of cost containment or reduction for this 
class of medicines. Results are sensitive to the list price of drugs.
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OBJECTIVES: Existing triage strategy is suboptimal in risk stratifying Asian 
patients with chest pain. Hence, we aim to determine the cost-effectiveness of an add-
on stress myocardial perfusion imaging (MPI) in improving risk stratiﬁ cation in a 
single-centre randomized controlled trial involving Asian patients with chest pain and 
non-diagnostic ECG presenting to an emergency department (ED) in Singapore. 
METHODS: Consenting patients were randomly assigned to with or without MPI 
add-on. Patients who developed ST segment changes, elevated CKMB/ Troponin 
during the 6-hr observation were admitted without receiving the assigned interven-
tions. One-year cost-effectiveness of the two strategies (MPI vs. no MPI) was analysed
from the institution’s perspective. Inpatient costs were obtained from electronic data-
base. Outpatient costs were estimated with expert input. Effectiveness was measured
as percent patients accurately risk stratiﬁ ed at one year (i.e. high/medium risk patients 
experiencing a cardiac event and low risk patients not experiencing any cardiac event
within one year). The incremental cost-effectiveness ratio (ICER) and conﬁ dence
intervals (CI) were constructed by bootstrap analysis (percentile approach). Sensitivity 
analysis was conducted for outpatient costs. RESULTS: Cost data were available from
1418 patients (83.9% of randomized patients). The ICER of MPI vs. no MPI was
$6,334 ($13,474 to $40). 97.6% of bootstrapped replicates fell below the $0 per
accurate risk stratiﬁ cation level, indicating that the scan strategy dominated the no 
scan strategy. All bootstrap replicates fell in the north- and south-east quadrants on
the cost-effectiveness plane, conﬁ rming that the negative ICER was due only to nega-
tive cost differences. Coefﬁ cient of variation (CV) of the effect difference is 0.19. Small 
bias to standard error ratio (0.013) justiﬁ es not making bias correction in estimating 
CI. Results were insensitive to outpatient costs. CONCLUSIONS: Add-on MPI is 
cost-effective in risk stratifying patients with chest pain. Given the small CV, bootstrap
estimates are likely to be robust.
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OBJECTIVES: To demonstrate how expert elicitation can be combined with Bayesian 
decision theory to inform the decision to conduct further research and identify efﬁ cient
research design when there is limited evidence available. METHODS: Using a model 
of enhanced external counterpulsation (EECP) for the treatment of angina, expert 
elicitation was used to provide informed priors on the key model parameters where 
no evidence was available. These priors were updated with sample information to 
quantify the expected value of sample information (EVSI). The EVSI was compared 
to the costs of sampling and the expected net beneﬁ t of sample information was
obtained (ENBS). The ENBS is a measure of the societal payoff to research and pro-
vides a sufﬁ cient condition for deciding to conduct more research. Given the need to
establish if EECP has a role for treating angina and the paucity of effectiveness 
evidence available, the ENBS was used to determine the type of study required, 
the optimal sample size, the appropriate length of follow-up and the endpoints 
that should be included. RESULTS: There is signiﬁ cant value to future research 
in EECP. This research is most valuable when directed towards establishing the
